Ìý
Click to expand view.
ACP is working actively in the field of performance measurement because we recognize its importance in the changing health care environment and want to shape its impact on Internal Medicine. The Performance Measurement Committee oversees the College's activities in this area.
The Performance Measurement Committee (PMC) applies criteria to assess the validity of performance measures for healthcare. The criteria are evaluated with a modified RAND-UCLA appropriateness method to determine whether they are evidence-based, methodologically sound, and clinically meaningful.
Latest Performance Measurement Committee Papers
ACP develops clinical policy papers and performance measurement commentaries published in scientific journals to educate ACP members about performance measurement initiatives.
- Ìý(Annals of Internal Medicine, 2025)
- (Annals of Internal Medicine, 2024)
- (Annals of Internal Medicine, 2024)
- (Annals of Internal Medicine, 2024)
- (Annals of Internal Medicine, 2023)
- (Annals of Internal Medicine, 2023)
- (Annals of Internal Medicine, 2021)
- (New England Journal of Medicine, 2018)
Help Us Improve Performance Measures
The PMC recognizes the burdens that inadequate measures can create for physicians. We are committed to continually reviewing and improving these measures to better support internal medicine physicians and drive meaningful change.
We value your input. Please take a minute to complete a
PMC Measure Reviews
This tool has been created to help you filter the reviewed performance measures.
= ACP Supports This Measure
= ACP Does Not Support This Measure: Uncertain Validity
= ACP Does Not Support This Measure
= ACP Does Not Support This Measure: Not Tested
Recent Measure Reviews
- Individual Clinician
- Group/Practice
- Health Plan
Diabetes: Eye Exam
Percentage of patients 18-75 years of age with diabetes and an active diagnosis of retinopathy in any part of the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or diabetics with no diagnosis of retinopathy in any part of the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or in the 12 months prior to the measurement period.
Date Reviewed: September 24, 2024
- Group/Practice
- Individual Clinician
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:
- All patients who were previously diagnosed with or currently have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR
- Patients aged 20 to 75 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR
- Patients aged 40-75 years with a diagnosis of diabetes; OR
- Patients aged 40 to 75 with a 10-year ASCVD risk score of > 20 percent
Date Reviewed: May 9, 2024
- Health Plan
Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Control (less than 8.0%)
The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) whose most recent HbA1c level is <8.0% during the measurement year.Date Reviewed: May 9, 2024
- Health Plan
Diabetes Monitoring for People with Diabetes and Schizophrenia
The percentage of patients 18 – 64 years of age with schizophrenia and diabetes who had both an LDL-C test and an HbA1c test during the measurement year
Date Reviewed: May 9, 2024
- Individual Clinician
Diabetes: Foot Exam
The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a foot exam (visual inspection and sensory exam with mono filament and a pulse exam) during the measurement year.
Date Reviewed: May 9, 2024
- Health Plan
Diabetes Screening for People with Schizophrenia or Bipolar Disorder who are Using Antipsychotic Medications (SSD)
The percentage of patients 18 – 64 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.
Date Reviewed: May 9, 2024
- Health Plan
- Group/Practice
- Individual Clinician
Kidney Health Evaluation
Percentage of patients aged 18-75 years with a diagnosis of diabetes who received a kidney health evaluation defined by an Estimated Glomerular Filtration Rate (eGFR) AND Urine Albumin-Creatinine Ratio (uACR) within the 12-month measurement period.Date Reviewed: May 9, 2024
- Group/Practice
Optimal Diabetes Care
The percentage of patients 18-75 years of age who had a diagnosis of type 1 or type 2 diabetes and whose diabetes was optimally managed during the measurement period as defined by achieving ALL of the following:
- HbA1c less than 8.0 mg/dL
- Blood Pressure less than 140/90 mmHg
- On a statin medication, unless allowed contraindications or exceptions are present
- Non-tobacco user
- Patient with ischemic vascular disease is on daily aspirin or anti-platelets, unless allowed contraindications or exceptions are present
Date Reviewed: May 9, 2024
- Health Plan
Emergency Department Visits for Hypoglycemia in Older Adults with Diabetes
For members 67 years of age and older with diabetes (types 1 and 2), the risk-adjusted ratio of observed to expected (O/E) emergency department (ED) visits for hypoglycemia during the measurement year. Two rates are reported:
- For all members 67 years of age and older with diabetes (types 1 and 2) the risk-adjusted ratio of O/E ED visits for hypoglycemia during the measurement year, stratified by dual eligibility.
- For a subset of members 67 years of age and older with diabetes (types 1 and 2) who had at least one dispensing event of insulin within each 180-day (6-month) treatment period from July 1 of the year prior to the measurement year through December 31 of the measurement year, the risk-adjusted ratio of O/E ED visits for hypoglycemia, stratified by dual eligibility.
Date Reviewed: May 9, 2024
- Health Plan
Statin Therapy for Patients with Diabetes
The percentage of members 40–75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:
- Received Statin Therapy. Members who were dispensed at least one statin medication of any intensity during the measurement year.
- Statin Adherence 80%. Members who remained on a statin medication of any intensity for at least 80% of the treatment period
Date Reviewed: May 9, 2024
- Individual Clinician
Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation
Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who had a neurological examination of their lower extremities within 12 months.
Date Reviewed: May 9, 2024
- Group/Practice
- Individual Clinician
Coronary Artery Disease: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy.
Date Reviewed: May 9, 2024
- Group/Practice
- Individual Clinician
- Health Plan
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)
Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.
Date Reviewed: May 9, 2024
- Health Plan
Comprehensive Diabetes Care: Blood Pressure Control (<140/90 mm Hg)
The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) whose most recent blood pressure level taken during the measurement year is <140/90 mm Hg.
Date Reviewed: May 9, 2024